BEAM250516P20000
- 1.60
- 0.000.00%
Beam Therapeutics Newsroom
Gene Therapy Developers Rise on Comments From FDA's Makary
$BEAM Stock Is up 9% Today. Here's What We See in Our Data.
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday
Beam Therapeutics Inc.'s (NASDAQ:BEAM) Recent 11% Pullback Adds to One-year Year Losses, Institutional Owners May Take Drastic Measures
Cathie Wood's ARK ETF Focuses on Beam Therapeutics, Coinbase Stock
FDA Staff Cuts Are Already Impacting Regulatory Work, Biotech Leaders Warn
Beam Therapeutics (BEAM) Moves 12.6% Higher: Will This Strength Last?
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80
Scotiabank Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $40
Express News | HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target
Beam Therapeutics Analyst Ratings
Beam Therapeutics' BEAM-302: Promising Clinical Data and Market Potential Drive Buy Rating
Reported Saturday, Beam Therapeutics Reports 91% Mean Correction Of Circulating AAT Protein At Day 28 In BEAM-302 Phase 1/2 Trial For AATD
Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress
Cathie Wood's Ark Invest Loads Up On Amazon, Coinbase: Offloads UiPath, Roblox
Cathie Wood's ARK Investment Buys 143K Shares of Beam Therapeutics Today
RBC Capital Maintains Beam Therapeutics(BEAM.US) With Hold Rating, Cuts Target Price to $20
Insider Sale: Chief Legal Officer of $BEAM Sells 5,674 Shares
RBC Cuts Price Target on Beam Therapeutics to $20 From $26, Keeps Sector Perform, Speculative Risk
Clear Street Initiates Beam Therapeutics(BEAM.US) With Buy Rating, Announces Target Price $34